Tevogen (TVGN) Bio filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio. “When combining our expertise across biopharma and artificial intelligence, we anticipate becoming a leader in the field with breakthroughs to follow,” said Tevogen Bio CEO Dr. Ryan Saadi, M.D., M.P.H. “We will provide additional updates about the company, including our AI effort, at the J.P. Morgan Healthcare Conference in January 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen announces additional responsibilities for key leaders
- Tevogen reports Q3 EPS (3c) vs (3c) last year
- Tevogen leverages Microsoft partnership to deliver target identification for HPV
- Tevogen regains compliance with Nasdaq
- Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz